February 22, 2022 7:58am
Pressure continues on market sentiment with additional confusion as earnings reporting ramps up
Pre-open indications: staying on the sidelines
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Earnings Reporting (this week) Dates: AxoGen AXGN) – Tuesday, 2/22, Global Blood Therapeutics (GBT) – Wednesday, 2/23, Sage Therapeutics (SAGE), Thursday, 2/24, Ionis Pharmaceuticals (IONS) - Thursday, 2/24, Sangamo Therapeutics (SGMO) - Thursday, 2/24, Editas Medicine (EDIT) - Thursday, 2/24
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts … I ask questions and note the indications
Dow futures are DOWN -0.13% (-45 points), S&P futures are DOWN -0.05% (-2.25 points) and NASDAQ futures are DOWN -0.44% (-61.75 points)
Stock futures tank in the pre-market on Tuesday morning, as Putin recognized Ukraine separatist regions as independent and deploys troops into those pro-Moscow regions of Ukraine,
European markets were sharply lower,
Asia Pacific markets also fell overnight, with Hong Kong’s Hang Seng index leading losses regionally, falling 3.11% in the afternoon trade.
Henry’omics:
Big earnings reporting week …
News that Biden was set to order sanctions on separatist regions of Ukraine, with the European Union vowing to take additional measures keeps traders wondering
Expectations of tighter monetary policy have also put pressure on stocks, particularly those in rate-sensitive sectors.
If you didn’t remember what happen at Friday’s close (Monday was a holiday), you won’t be prepared for today’s session,
RegMed Investors’ (RMi) closing bell: “what has changed, an escalation of fears. Yet another cell and gene therapy sector sell-off facilitated by risk appetites, option expiration and the Ruskies” … https://www.regmedinvestors.com/articles/12309
Ebb and flow –
· February stats: 9 negative and 5 positive closes
· January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306
Companies in my headlights – It’s your decision; I provide ideas and context:
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed down Friday -$0.68 to $3.88 with 103 shares traded after Thursday’s +$0.06 with 700 shares traded after Wednesday -$0.06 (had been -$0.98) with 420 shares traded, Tuesday’s flat with 200 shares traded and Monday’s flat with 1,899 shares traded
· WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
· Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: Dangerous winds of war and sanctions are out there undermining market and sector confidence.
To add to the chaos and uncertainty, this week has “heavy” earnings reporting
Earnings’ reporting:
· AxoGen AXGN) – Tuesday, 2/22
· Global Blood Therapeutics (GBT) – Wednesday, 2/23
· Sage Therapeutics (SAGE), Thursday, 2/24
· Ionis Pharmaceuticals (IONS) - Thursday, 2/24
· Sangamo Therapeutics (SGMO) - Thursday, 2/24
· Editas Medicine (EDIT) - Thursday, 2/24
· Fate Therapeutics, Monday, 2/28
· BioLife Solutions (BLFS), Monday,2/28
· Athersys (ATHX), Tuesday, 3/15
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
